Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Case Rep
Hauptverfasser: Klein, Klara, Asaad, Shonda, Econs, Michael, Rubin, Janet E
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2018
Schlagworte:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/
https://ncbi.nlm.nih.gov/pubmed/29298794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge